USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: LITRON LABORATORIES, LTD.
City: ROCHESTER
State: NY
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,900,977.00 21
SBIR Phase II $5,567,332.00 10

Award List:

HYBRID CELL FORMATION BY TARGETED ELECTROFUSION

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: NSF
Principal Investigator: Andrew M Tometsko Phd , Director Of Research
Award Amount: $40,000.00

GENETIC TOXICOLOGY TESTING BY HIGH-SPEED FLOW CYTOMETRY

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrew M Tometsko , Principal Investigator
Award Amount: $50,000.00

GENETIC TOXICOLOGY TESTING BY HIGH-SPEED FLOW CYTOMETRY

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Andrew M Tometsko , Principal Investigator
Award Amount: $293,000.00
Abstract:
Genotoxic chemicals are an existing widespread health hazardto the human population. advances in genetic toxicology testing have made it possible to assay potential mutagens, carcinogens, teratogens, and clastogens in the environment. however, many currently available mammalian cell tests are… More

HYBRID CELL FORMATION BY TARGETED ELECTROFUSION

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: NSF
Principal Investigator: Andrew M Tometsko Phd , Director Of Research
Award Amount: $200,000.00
Abstract:
Cell fusion provides biotechnologists with the ability to generate unique cell types by mixing the genetic material oftwo parent cells. the generation of immortal antibody producting hybridomas by fusing antibody producing spleen cells with myeloma cells provides an example of the utility of cell… More

RAPID PRODUCTION OF TUMOR SPECIFIC HYBRIDOMAS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tometsko, Andrew M , Principal Investigator
Award Amount: $50,000.00
Abstract:
Mabs are homogeneous proteins that recognize specific epitopes on an antigen (e. g., a soluble protein or a cellular component). because of their specificity, mabs can provide the scientist with highly selective reagents that can be used for diagnostic and/or therapeutic applications. an antibody… More

Analyzing Toxicity to Mammalian Cells by Flow Cyometry

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dorothea Torous
Award Amount: $78,415.00

Analyzing Toxicity to Mammalian Cells by Flow Cyometry

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Dorothea Torous
Award Amount: $429,497.00
Abstract:
Our Phase I research program is based on years of research which strongly suggest that high speed f(FCM) is a technology that can significantly improve toxicity assays. Highly reliable clastogen andhave been developed in our laboratories where FCM has played a major role in processing and… More

FLOW CYTOMETRIC ANEUGEN AND CLASTOGEN ASSAY

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Torous, Dorothea K
Award Amount: $81,125.00

FLOW CYTOMETRIC RAT MICRONUCLEUS ASSAY

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Torous, Dorothea K
Award Amount: $98,410.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dorothea Torous
Award Amount: $99,376.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dorothea K. Torous
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Dorothea K. Torous
Award Amount: $377,754.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $99,579.00

Flow Cytometric Method to Analyze Micronuclei

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dorothea K. Torous
Award Amount: $0.00

Flow Cytometric Method to Analyze Micronuclei

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Dorothea K. Torous
Award Amount: $265,514.00

MEASURING CYTOGENETIC DAMAGE IN HUMAN BLOOD

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $0.00
Abstract:
Humans are exposed to genotoxic agents through a variety of sources. Micronucleus (MN) formation is an endpoint which can be used to detect DNA damage resulting from clastogenic or aneugenic mechanisms. A sensitive and high throughput system to measure human blood for MN would have a myriad of… More

MEASURING CYTOGENETIC DAMAGE IN HUMAN BLOOD

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $483,062.00
Abstract:
Humans are exposed to genotoxic agents through a variety of sources. Micronucleus (MN) formation is an endpoint which can be used to detect DNA damage resulting from clastogenic or aneugenic mechanisms. A sensitive and high throughput system to measure human blood for MN would have a myriad of… More

AUTOMATION OF THE IN VITRO MICRONUCLEUS ASSAY

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $98,597.00
Abstract:
The in vitro nucleus test is increasingly being used as an alternative to the more costly and time consuming in vitro chromosome aberration assay as a screen for detecting a chemical's genotoxic potential (aneugenic or clastogenic activity which are associated with disorders such as Down's Syndrome,… More

Automation of the vitro Micronucleus Assay

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $423,418.00
Abstract:
DESCRIPTION (provided by applicant): The induction of DNA damage and the resulting sequelae of mutations and chromosomal rearrangements are primary mechanisms by which cancers arise. DNA damage has also been implicated in arteriosclerosis and certain birth defects. Thus, there is an important… More

Assessing toxicity with an ex vivo erythropoiesis system

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Francis G. Murante
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Humans are exposed to toxic chemical and physical agents through a variety of sources. Of extreme concern are agents which can damage DNA, as genotoxicity is associated with cancer, atherosclerosis, and birth defects. The research effort proposed herein is aimed… More

In vivo mutation assay based on pig-a locus

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $92,480.00
Abstract:
DESCRIPTION (provided by applicant): Mutation to DNA is a primary mechanism by which cancers arise. These events have also been implicated in diseases such as atherosclerosis, and processes such as aging. Therefore, there is an important need for sensitive methods which are capable of… More

Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $133,336.00
Abstract:
DESCRIPTION (provided by applicant): This research project addresses an important problem faced by the chemical and drug industries? their requirement to evaluate the DNA damaging potential of ever larger numbers of new chemical entities in shorter periods of time. This situation presents… More

High Throughput Radiation Biodosimetry

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $126,058.00
Abstract:
DESCRIPTION (provided by applicant): In instances of accidental radiation exposure or radiological terror events, incomplete or missing physical dosimetry will be the norm. Biodosimetry is therefore needed to make rational clinical management decisions, an d for long-term carcinogenic risk… More

Versatile Mutation Assay Platform

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $123,701.00
Abstract:
DESCRIPTION (provided by applicant): DNA mutation is a primary mechanism by which cancers arise. Alterations of genetic material have also been implicated in diseases such as atherosclerosis, and processes such as aging. Thus, there is an important need f or sensitive analytical methods which… More

Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $919,965.00
Abstract:
DESCRIPTION (provided by applicant): This research project addresses an important problem faced by the chemical and drug industries-their requirement to evaluate the DNA damaging potential of ever increasing numbers of new chemical entities in shorter peri ods of time. This situation presents… More

Versatile Mutation Assay Based on the Pig-A Locus

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $767,944.00
Abstract:
DESCRIPTION (provided by applicant): Mutation to DNA is a primary mechanism by which cancers arise. These events have also been implicated in diseases such as atherosclerosis, and processes such as aging. Therefore, there is an important need for sensitive analytical methods which facilitate the… More

Validation of a Rodent Mutagenicity Assay

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger
Award Amount: $348,293.00
Abstract:
DESCRIPTION (provided by applicant): Mutation to DNA is a primary mechanism by which cancers arise. These events have also been implicated in diseases such as atherosclerosis, and processes such as aging. Therefore, there is an important need for sensitive analytical methods that facilitate the… More

Rapid Radiation Dose Estimation

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jeffrey C. Bemis
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Human exposure to radiation, whether by accidental or intentional use, has the potential to impact large populations and severely tax the facilities and resources mandated to respond to such incidents. The current state of clinical management of radiation… More

Validation of a Rodent Mutagenicity Assay

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stephen D. Dertinger – 585-442-0930
Award Amount: $1,407,178.00
Abstract:
DESCRIPTION (provided by applicant): Mutation to DNA is a primary mechanism by which cancers arise. These events have also been implicated in diseases such as atherosclerosis, and processes such as aging. Therefore, there is an important need for sensitiveanalytical methods that facilitate the study… More

Rapid Assessment of Radiation Exposure

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger – 585-442-0930
Award Amount: $481,619.00
Abstract:
DESCRIPTION (provided by applicant): Large-scale disaster situations put considerable demands on existing medical infrastructure, as well as local governing and safety agencies. When the additional factor of ionizing radiation and exposure of humans is part of the emergency, the lack of effective… More

Tools to Study Mammalian Mutagenesis

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen D. Dertinger – 585-442-0930
Award Amount: $199,988.00
Abstract:
DESCRIPTION (provided by applicant): Despite the extensive work being performed to understand cancer and carcinogenic properties of chemicals and other agents, there are still gaps in our ability to efficiently identify carcinogens, and elucidate their mode(s) of action. The current state of… More